A Phase 1 interventional study of MAM01 1.5 mg/kg and Placebo in Malaria, sponsored by Gates Medical Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.
Among the 105 studies in Malaria with a site in United States, this one is the 34th largest by enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2023, is one of 62 in phase 1, and was the 97th registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–54 · Healthy volunteers
Johns Hopkins Bloomberg School of Public Health · Sites in United States, Zambia
Ages 1 mo–59 mo
Amivas (US), LLC · Sites in United States
Ages 15–100 · Women only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–70 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 20 · Phase 3 2 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 45 across the 89 interventional studies, 324 across the 15 observational. Of the 92 that completed or were terminated, 22 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 105 have an industry lead sponsor. The 10 most frequent:
Gates Medical Research Institute is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Gates Medical Research Institute has 2 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Malaria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05711485Johns Hopkins Bloomberg School of Public HealthPlatelet-Directed Whole Blood Transfusion Strategy for Malaria | 2027-04-30 |
| NCT06854042Eisai Inc.A Study of Oral E1018 in Healthy Adult Participants | 2027-07-22 |
| NCT06607003National Institute of Allergy and Infectious Diseases (NIAID)Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 105 studies in Malaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a First-in-Human (FiH), randomized, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP). This study will evaluate the safety, tolerability, pharmacokinetics (PK), and protective efficacy of MAM01, as well as safety and PK of repeat subcutaneous (SC) dosing. Part A will have a double-blind, placebo-controlled design. Part B will randomize participants to one of three open-label MAM01 dose groups; a separate non-randomized group will be enrolled to include participants who will receive no treatment and act as infectivity controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Both males and females are eligible to participate as per the following:
a. Female participants physically capable of pregnancy, have at least one negative pregnancy test during Screening, on the day of enrollment, prior to product (IP) administration, prior to CHM and at the start of antimalarial treatment, and who agree to use effective to avoid pregnancy from 28 days before enrollment through 10 months after last administration of investigational product are eligible to participate.
Exclusion criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 sentinel participants will be randomized in a 1:1 ratio to receive MAM01 1.5 milligrams per kilogram (mg/kg) IV or placebo. Following at least a 24-hour safety review period, the 6 remaining participants of Cohort 1 will be randomized in a 5:1 ratio to receive MAM01 1.5 mg/kg IV or placebo.
Biological: MAM01 1.5 mg/kg · Biological: Placebo
7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg SC or placebo
Biological: MAM01 5 mg/kg · Biological: Placebo
7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg IV or placebo.
Biological: Placebo · Biological: MAM01 5 mg/kg
8 participants will be randomly assigned in a 6:2 ratio to receive MAM01 10 mg/kg IV or placebo.
Biological: Placebo · Biological: MAM01 10 mg/kg
7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 40 mg/kg IV or placebo
Biological: Placebo · Biological: MAM01 40 mg/kg
Participants from Cohort 2 and from Cohort 3 will receive 5 mg/kg MAM01 SC.
Biological: MAM01 5 mg/kg
6 participants will receive a 450 mg SC dose of MAM01. The dose was selected by applying a PK-pharmacodynamic (PD) model from the Part A data to estimate a (data-driven) protection threshold at Controlled Human Malaria Infection (CHMI).
Biological: MAM01 450 mg
8 participants will receive a 600 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI
Biological: MAM01 600 mg
8 participants will receive 900 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI.
Biological: MAM01 900 mg
6 participants will be enrolled into a non-randomized group prior to CHMI. These participants will receive no treatment and act as infectivity controls
Other: Control
1.5 mg/kg MAM01 will be administered via IV route.
Placebo will be administered via IV route.
5 mg/kg MAM01 will be administered via SC route.
10 mg/kg MAM01 will be administered via IV route.
40 mg/kg MAM01 will be administered via IV route.
MAM01 will be administered via SC route.
Placebo will be administered via SC route.
5 mg/kg MAM01 will be administered via IV route.
No drug or placebo will be administered.
MAM01 will be administered via SC route.
MAM01 will be administered via SC route.
Number of Participants Reporting Solicited Adverse Events (AEs) in the Subcutaneous Cohorts
Solicited AEs were defined events participants were specifically asked about, which were recorded by participants in the memory aid card. Solicited AES included local injection site AEs (pain, redness, swelling, itching and bruising) and systemic AEs (fever, chills, headache, fatigue, nausea, muscle pain and joint pain). A Solicited AE does not necessarily have a causal relationship with the intervention.
Time frame: Day 1 to Day 7 post dose
Number of Participants Reporting Unsolicited Adverse Events
In this study an unsolicited AE is any AE not captured as a solicited AE in the Memory Aid Card between Day 0 and Day 7 after MAM01 dosing, and all AEs occurring after Day 7 post dose were collected as Unsolicited AEs.
Time frame: Through Day 28 post dose
Number of Participants Reporting Serious Adverse Events (SAEs) Including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events Special Interest (AESIs)
A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
Time frame: Up to Day 168
Number of Participants Who Received 2 Doses Reporting SUSARs, SAEs and AESIs
A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
Time frame: Through Day 336
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters
Blood samples were collected for the assessment of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total carbon-dioxide (CO2), chloride, total bilirubin, creatinine, blood urea nitrogen, glucose, albumin, total protein, sodium and potassium.
Time frame: Through Day 336
Number of Participants With Clinically Significant Changes in Hematology Parameters
Blood samples were collected for the assessment of complete blood count (CBC) including hemoglobin, platelet count, and white blood cell counts, and differential to include the absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes.
Time frame: Through Day 336
Maximal Observed Concentration (Cmax) Following Single Dose of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Cmax Following Repeat Dosing of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
AUC (0-t) Following Repeat Dosing of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Concentration at the Time of CHMI (CCHMI) of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Blood Terminal Elimination Rate Constant (λz) of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Terminal Half Life (t1/2) Following Single Dose of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
t1/2 Following Repeat Dosing of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224, 280 and 378 post-dose
Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM01
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics. The accumulation ratio was calculated as the ratio of AUC (0-168) (post first dose) to AUC (210-378) (post redose).
Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose
Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI
The characterization of protective efficacy against Pf following CHMI challenge, was assessed by evaluating the presence or absence of Pf infection as determined by qRT-PCR after CHMI (planned through 4 weeks post-CHMI) and evaluating the time to parasitemia after CHMI in each cohort.
Time frame: Up to Day 27 post-CHMI
Time to Parasitemia After CHMI
Parasitemia was assessed by qRT-PCR up to Day 27 following CHMI. In addition, a thick blood smear was prepared for microscopic analysis, which was examined only once the first qRT-PCR sample tested positive. Daily parasitemia monitoring continued until the participant had a confirmed initial positive qRT-PCR. The first positive qRT-PCR triggered either a second PCR test or microscopic analysis of the blood smear. Once two positive results were obtained, rescue therapy was initiated.
Time frame: Up to Day 27 post-CHMI
Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Time frame: Up to Day 280
Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Time frame: Up to Day 378
Cohort 6: Numbers of Participants With Seroconversion
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
Time frame: Up to Day 84
A two-part randomized, dose-escalation study to assess anti-malarial human monoclonal antibody MAM01 in healthy, malaria-naïve adults. Part A: double-blind, placebo-controlled, single-ascending dose (SAD) study, while Part B: dose expansion was open-label. The study evaluated safety, tolerability, pharmacokinetics, and protective efficacy of MAM01 against controlled human malaria infection (CHMI) with Plasmodium falciparum NF54. Safety and PK of repeat subcutaneous dosing were also evaluated.
| Milestone | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 7 | 1 | 6 | 7 | 6 | 6 |
| Received sc dose | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Completed | 5 | 4 | 5 | 6 | 6 | 5 | 1 | 6 | 6 | 6 | 6 |
| Not completed | 1 | 2 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Move from study area- | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Solicited AEs were defined events participants were specifically asked about, which were recorded by participants in the memory aid card. Solicited AES included local injection site AEs (pain, redness, swelling, itching and bruising) and systemic AEs (fever, chills, headache, fatigue, nausea, muscle pain and joint pain). A Solicited AE does not necessarily have a causal relationship with the intervention.
| Participants | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC | Part A: Placebo Then SC Repeat Dose MAM01 5 mg/kg | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|
| Any injection site symptom | 0 | 0 | 2 | 0 | 2 | 2 | 3 |
| Any general body symptom | 1 | 0 | 2 | 0 | 1 | 1 | 2 |
In this study an unsolicited AE is any AE not captured as a solicited AE in the Memory Aid Card between Day 0 and Day 7 after MAM01 dosing, and all AEs occurring after Day 7 post dose were collected as Unsolicited AEs.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Unsolicited Adverse Events | 3 | 6 | 4 | 4 | 4 | 4 | 0 | 4 | 2 | 5 | 3 |
A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any SAE | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any SUSAR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any AESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.
| Participants | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| Any SAE | 0 | 0 |
| Any SUSAR | 0 | 0 |
| Any AESI | 0 | 0 |
Blood samples were collected for the assessment of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total carbon-dioxide (CO2), chloride, total bilirubin, creatinine, blood urea nitrogen, glucose, albumin, total protein, sodium and potassium.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected for the assessment of complete blood count (CBC) including hemoglobin, platelet count, and white blood cell counts, and differential to include the absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Hematology Parameters | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| micrograms per milliliter | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Maximal Observed Concentration (Cmax) Following Single Dose of MAM01 | 19.5 ± 13.9 | 33.1 ± 30.8 | 58.1 ± 8.6 | 122 ± 15.7 | 513 ± 10.0 | 46.0 ± 18.5 | 62.7 ± 8.4 | 95.6 ± 25.6 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| micrograms per milliliter | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| Cmax Following Repeat Dosing of MAM01 | 42.8 ± 4.2 | 40.4 ± 9.0 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| day*micrograms per milliliter | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01 | 1448.7 ± 22.6 | 3154.5 ± 35.1 | 5054.9 ± 18.1 | 10997.7 ± 17.5 | 43082.1 ± 14.7 | 2734.4 ± 24.0 | 3408.6 ± 31.7 | 6018.7 ± 22.0 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| day*micrograms per milliliter | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| AUC (0-t) Following Repeat Dosing of MAM01 | 4008.3 ± 14.8 | 4082.9 ± 15.7 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| day*micrograms per milliliter | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01 | 1481.4 ± 10.0 | 2962.8 ± 32.0 | 4503.9 ± 18.0 | 9197.7 ± 17.1 | 31934.1 ± 15.1 | 1323.4 ± 18.9 | 1658.4 ± 15.6 | 2771.4 ± 23.2 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| micrograms per milliliter | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Concentration at the Time of CHMI (CCHMI) of MAM01 | 3.02 ± 15.4 | 7.00 ± 39.4 | 13.2 ± 34.9 | 31.2 ± 23.3 | 119 ± 30.8 | 36.0 ± 18.3 | 40.3 ± 45.4 | 77.3 ± 20.4 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| 1/day | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Blood Terminal Elimination Rate Constant (λz) of MAM01 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| Days | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| Terminal Half Life (t1/2) Following Single Dose of MAM01 | 70.7 ± 9.3 | 68.1 ± 14.9 | 74.3 ± 15.5 | 70.7 ± 12.5 | 71.7 ± 17.0 | — | NA ± NA | — |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| Days | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| t1/2 Following Repeat Dosing of MAM01 | 67.2 ± 0.4 | 56.0 ± 3.0 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| day*micrograms per milliliter | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC | Part A (SAD Cohort 3): MAM01 5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|---|---|---|---|---|
| AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01 | 1781 ± 10.8 | 3738 ± 38.6 | 5335 ± 20.0 | 12467 ± 19.2 | 49011 ± 17.7 | — | NA ± NA | — |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.
| Unitless | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01 | NA ± NA | 0.692 ± 13.6 |
Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics. The accumulation ratio was calculated as the ratio of AUC (0-168) (post first dose) to AUC (210-378) (post redose).
| Ratio | Part A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SC | Part A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC |
|---|---|---|
| Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM01 | 1.29 ± 15.7 | NA ± NA |
The characterization of protective efficacy against Pf following CHMI challenge, was assessed by evaluating the presence or absence of Pf infection as determined by qRT-PCR after CHMI (planned through 4 weeks post-CHMI) and evaluating the time to parasitemia after CHMI in each cohort.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI | 3 | 5 | 5 | 5 | 0 | 5 | 1 | 4 | 6 | 4 | 6 |
Parasitemia was assessed by qRT-PCR up to Day 27 following CHMI. In addition, a thick blood smear was prepared for microscopic analysis, which was examined only once the first qRT-PCR sample tested positive. Daily parasitemia monitoring continued until the participant had a confirmed initial positive qRT-PCR. The first positive qRT-PCR triggered either a second PCR test or microscopic analysis of the blood smear. Once two positive results were obtained, rescue therapy was initiated.
| Days | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Parasitemia After CHMI | 9 (7 to 11) | 7 (7 to 10) | 9 (9 to 11) | 10 (8 to 11) | NA (NA to NA) | 7 (7 to 7) | 7 (NA to NA) | 9 (7 to NA) | 8 (NA to NA) | 9.5 (9 to NA) | 7 (NA to NA) |
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
| Participants | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV |
|---|---|---|---|
| Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion | 0 | 0 | 0 |
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
| Participants | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) |
|---|---|---|
| Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion | 0 | 0 |
The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.
| Participants | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC |
|---|---|---|---|
| Cohort 6: Numbers of Participants With Seroconversion | 0 | 0 | 0 |
Collected over Solicited AEs collected daily from Day 1 to Day 7 post dose (included injection site pain, redness, swelling, itching, bruising, fever, chills, headache, fatigue, nausea, muscle pain and joint pain) Unsolicited AEs were collected for 28 days after each dose. SAEs were collected from Screening through End of Study (Day 378 for Part A and Day 84 for Part B).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A (SAD Cohort 4): MAM01 10 mg/kg IV | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A (SAD Cohort 5): MAM01 40 mg/kg IV | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part A: Placebo | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Part A: Infectivity Controls | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part B: Infectivity Controls | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Event | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression suicidalPsychiatric disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/1 | 0/6 | 0/6 | 0/6 | 0/6 |
| Event | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/1 | 1/6 | 2/6 | 1/6 | 0/6 |
| Injection site rednessGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/1 | 1/6 | 0/6 | 2/6 | 0/6 |
| Injection site bruisingGeneral disorders | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/7 | 0/1 | 0/6 | 1/6 | 1/6 | 0/6 |
| Respiratory tract infection viralInfections and infestations | 1/6 | 2/6 | 1/6 | 0/6 | 1/6 | 0/7 | 0/1 | 0/6 | 0/6 | 0/6 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/7 | 0/1 | 0/6 | 0/6 | 2/6 | 0/6 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/1 | 1/6 | 0/6 | 1/6 | 2/6 |
| HeadacheNervous system disorders | 1/6 | 1/6 | 2/6 | 1/6 | 2/6 | 2/7 | 0/1 | 1/6 | 1/6 | 1/6 | 0/6 |
| Muscle painMusculoskeletal and connective tissue disorders | 1/6 | 1/6 | 1/6 | 0/6 | 1/6 | 1/7 | 0/1 | 1/6 | 0/6 | 2/6 | 0/6 |
| FatigueGeneral disorders | 0/6 | 1/6 | 1/6 | 1/6 | 1/6 | 2/7 | 0/1 | 1/6 | 1/6 | 1/6 | 0/6 |
| LymphadenopathyBlood and lymphatic system disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/7 | 0/1 | 1/6 | 0/6 | 0/6 | 0/6 |
Safety Population comprised of all participants who were randomly assigned to a trial intervention and received the intervention, and the untreated infectivity control participants. One participant in Cohort 6 Group 2: MAM01 600 mg/kg discontinued from the trial (withdrew consent) prior to dosing.
| Age, Continuous(Years) | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 28.5 ± 4.28 | 26.8 ± 7.08 | 35.3 ± 7.58 | 32.7 ± 8.55 | 32.3 ± 8.19 | 29.1 ± 7.29 | 27.0 ± NA | 36.5 ± 10.37 | 38.0 ± 8.44 | 31.8 ± 5.91 | 32.8 ± 8.18 | 32.7 ± 7.76 |
| Sex: Female, Male(Participants) | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 4 | 5 | 2 | 1 | 5 | 1 | 2 | 3 | 31 |
| Male | 4 | 3 | 3 | 2 | 1 | 5 | 0 | 1 | 5 | 4 | 3 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 5 |
| Not Hispanic or Latino | 6 | 5 | 5 | 5 | 6 | 7 | 1 | 4 | 6 | 6 | 6 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV | Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC) | Part A (SAD Cohort 4): MAM01 10 mg/kg IV | Part A (SAD Cohort 5): MAM01 40 mg/kg IV | Part A: Placebo | Part A: Infectivity Controls | Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC | Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC | Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC | Part B: Infectivity Controls | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 4 | 0 | 0 | 0 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 1 | 3 | 11 |
| White | 2 | 3 | 3 | 6 | 1 | 6 | 1 | 1 | 3 | 5 | 3 | 34 |
| More than one race | 1 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Dec 2024, 15 months.
Results were first posted in Jun 2026, 1 year 5 months after primary completion.
Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 15 months is above that.
Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gates Medical Research Institute